AU2014361814A1 - Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders - Google Patents

Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders Download PDF

Info

Publication number
AU2014361814A1
AU2014361814A1 AU2014361814A AU2014361814A AU2014361814A1 AU 2014361814 A1 AU2014361814 A1 AU 2014361814A1 AU 2014361814 A AU2014361814 A AU 2014361814A AU 2014361814 A AU2014361814 A AU 2014361814A AU 2014361814 A1 AU2014361814 A1 AU 2014361814A1
Authority
AU
Australia
Prior art keywords
agx51
cancer
compound
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014361814A
Other languages
English (en)
Inventor
Jaideep Chaudhary
William A. Garland
Glen STOLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenex Inc
Original Assignee
Angiogenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenex Inc filed Critical Angiogenex Inc
Publication of AU2014361814A1 publication Critical patent/AU2014361814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014361814A 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders Abandoned AU2014361814A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361916116P 2013-12-13 2013-12-13
US61/916,116 2013-12-13
US201461965776P 2014-02-06 2014-02-06
US61/965,776 2014-02-06
PCT/US2014/070221 WO2015089495A2 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Publications (1)

Publication Number Publication Date
AU2014361814A1 true AU2014361814A1 (en) 2016-07-28

Family

ID=53371974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014361814A Abandoned AU2014361814A1 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Country Status (6)

Country Link
EP (1) EP3079680A4 (cg-RX-API-DMAC7.html)
JP (2) JP2017506257A (cg-RX-API-DMAC7.html)
CN (1) CN107847470A (cg-RX-API-DMAC7.html)
AU (1) AU2014361814A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016007748A (cg-RX-API-DMAC7.html)
WO (1) WO2015089495A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) * 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
EP3760614B8 (en) * 2019-07-02 2022-04-27 Universität Heidelberg Chemical inhibitors of id proteins for the treatment of cancer and other diseases
JP7880815B2 (ja) * 2019-10-01 2026-06-26 メモリアル スローン-ケタリング キャンサー センター Idタンパク質の小分子阻害剤
CN113627763B (zh) * 2021-07-30 2023-12-01 厦门大学 一种风险量化评估模型建立方法
CN114480490A (zh) * 2021-12-31 2022-05-13 四川省医学科学院·四川省人民医院 一种构建视网膜新生血管性疾病动物模型的方法
CN115487358B (zh) * 2022-08-05 2023-05-30 核工业四一六医院 一种用于软骨组织修复的凝胶复合支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
US20130171158A1 (en) * 2010-06-30 2013-07-04 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Also Published As

Publication number Publication date
CN107847470A (zh) 2018-03-27
WO2015089495A2 (en) 2015-06-18
EP3079680A2 (en) 2016-10-19
MX2016007748A (es) 2017-07-28
JP2017506257A (ja) 2017-03-02
WO2015089495A3 (en) 2015-11-12
EP3079680A4 (en) 2017-11-22
JP2019203028A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
JP2019203028A (ja) 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法
Zhang et al. Polo-like kinase 4’s critical role in cancer development and strategies for Plk4-targeted therapy
EP4186501B1 (en) Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits
JP2023145689A (ja) Her2陽性がんの処置
WO2009051801A2 (en) Chemical inhibitors of inhibitors of differentiation
ES2992827T3 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
JP7611701B2 (ja) Abcb5のリガンドおよび基質
JP2022180472A (ja) 癌のための併用療法
EP3003356B1 (en) Il-1 antagonists for use in treating alzheimer's disease
WO2016040877A1 (en) Human dosing of phosphatase inhibitor
US20140348819A1 (en) Methods of Treating Cancer
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
ES2905360T3 (es) Composiciones y métodos para detectar, tratar y prevenir enfermedades y trastornos
CN105377295A (zh) 基于caix分级的癌症治疗
US20190111111A1 (en) Treatment of Cerebral Cavernous Malformations
Yu et al. Elevation of the chemokine pair CXCL10/CXCR3 initiates sequential glial activation and crosstalk during the development of bimodal inflammatory pain after spinal cord ischemia reperfusion
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
Alexandraki et al. Medical therapy for craniopharyngiomas
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
WO2004043340A2 (en) Alpha 5 beta 1 and its ability to regulate the cell survival pathway
van Genugten et al. Imaging the rewired metabolism in lung cancer in relation to immune therapy
US20200023038A1 (en) Method of treating neoplasias
KR20260008112A (ko) 파르네실트랜스퍼라제 억제제 및 pi3k 억제제를 사용한 편평 세포 암종의 치료 방법
CN120265328A (zh) 用于非小细胞肺癌的检测和治疗的方法
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application